Sanofi rolls out new Priftin packaging

BRIDGEWATER, N.J. — Sanofi on Tuesday announced new 24- and 32-count packages for its Priftin (rifapentine), a treatment for latent tuberculosis infection in patients at high risk for tuberculosis and children older than 2 years of age.

Both packages contain blister packs with individually perforated tablet blisters and individual tablet printing on the backing foil. Both also come with an extended shelf life of up to three years.

“For more than fifty years, Sanofi has provided treatment and programs that equip patients and their healthcare providers to fight TB,” Sanofi’s global chief medical officer DR. Paul Chew said. “We are proud to introduce packaging and extended shelf-life that reinforces our sustained commitment to the TB community.”

According to Sanofi, patients with LTBI have the bacteria that causes TB, but wont’ show symptoms or feel sick, nor will they spread the disease. However, of the 13 million Americans with LTBI, some 5% to 10% will develop TB if they go untreated. Priftin is an antimycobacterial that can treat LTBI in combination with isoniazide. For information about who should get tested, see the infographic below.